Abstract: A method performed at a computer system includes: obtaining door lock activation data for a door of a dwelling of the user; obtaining current occupancy data for the dwelling; setting a configuration of a controller for the dwelling, based at least in part on the door lock activation data for the door and the current occupancy data for the dwelling; the first configuration including for each sensor in a set of sensors coupled to the controller, disabling the sensor or disabling alerts from the sensor.

Abstract: Certain aspects of the present disclosure provide techniques for electric vehicle charging management. In one example, a method includes: building a graph representing an electrical topology of the electric vehicle charging facility and producing an updated graph by updating a state of the one or more network nodes based on electric current or power flow through the one or more passive electric components and updating a state of the one or more component nodes based on electric current or power produced or consumed by the one or more active electric components. The method further includes receiving a selected control strategy for the electric vehicle charging facility and adjusting an electric current or a power draw of an electric vehicle charging station in the electric vehicle charging facility based on the updated graph and the selected control strategy.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: Apparatus and methods for mitigation and control of inflammatory responses during usage of an implantable sensor device. In one exemplary embodiment, the implantable sensor device includes a drug-eluting component configured to release a varying amount of anti-inflammatory substance(s) (such as corticosteroid) over the lifetime of the implant, such as according to a desired elution profile. In one variant, this component is also an analyte-permeable membrane used as part of a detector of the implant. Inhibition of inflammation in the tissue improves availability of analytes (such as oxygen and glucose) to the sensor in addition to reducing fibrous encapsulation. Various modifications to the elution rate, and configuration of the implant, allow optimized control over undesirable effects such as foreign body reactions (FBR) or other inflammatory responses which may reduce usable implant lifetime.

Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.

Abstract: Example medical devices and methods of making example medical devices are disclosed. An example medical device includes a frame configured to be secured to cardiac tissue, wherein the frame includes a fatigue resistant nickel-titanium alloy that is heat set at a temp in the range of 450-550 degrees Celsius.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract: Techniques described herein can be used to provide recommendations for multiple users. In particular, one or more users may interact with an interactive device to stream media content or utilize other services provided by a service provider. The users may provide commands to the interactive device to request content from a service provider. Contextual data associated with the request may be used to determine that an audience of the interactive device comprises more than one user. Based on this determination, content recommendations can be provided so that the recommendations are more likely to be suitable for the audience.

Abstract: Described herein are online services provided to users based on the current context information of the users. In particular, a user may interact with an interactive device to stream media content from a remote service provider. The user may provide commands to the interactive device using a voice command. The interactive device may transmit requests based on such user command. In order for the service providers to provide customized services, the interactive device can be configured to capture additional contextual data indicative of an environment of the user such as ambient sound and provide such contextual data to the service provider. The service provider can utilize such contextual data to generate content recommendations suitable to the current context of the request or command or user.

Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract: A system and a method of using the system for reproducibly cutting a cove using a table saw are presented. The system comprises a first fence assembly and a fixturing means, where the fence assembly is rotatably affixed to the fixturing means, wherein the fixturing means can be releasably secured to the table of the table saw. The method comprises providing a blank molding, a table saw having a table and saw blade, and the cove system and releasably affixing the cove system to the table. The method further comprises setting a fence angle using the first fence assembly and setting a fence depth by adjusting the position of the fixturing means with respect to the table. The method finally comprises feeding the blank molding over the saw blade thereby cutting a cove in the blank molding.

Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

Abstract: The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-K? inhibitors and/or PI3-K?/mTOR dual inhibitors.